O1-5-2Disease flare phenomenon after multi-tyrosine kinase inhibitor discontinuation: a retrospective analysis
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Oncology"
DOI: 10.1093/annonc/mdx697.011
Abstract: lung, and it was significantly associated with shorter survival rate after curative surgery. In addition, URST1 was expressed in 64 of 96 (66.7%) oral cancers, but not in oral mucosa, and it was significantly correlated… read more here.
Keywords: inhibitor; flare phenomenon; analysis; 2disease flare ... See more keywords
Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
Sign Up to like & getrecommendations! Published in 2019 at "OncoTargets and therapy"
DOI: 10.2147/ott.s189391
Abstract: Human malignancies are often the result of overexpressed and constitutively active receptor and non-receptor tyrosine kinases, which ultimately lead to the mediation of key tumor-driven pathways. Several tyrosine kinases (ie, EGFR, FGFR, PDGFR, VEGFR), are… read more here.
Keywords: human malignancies; multi tyrosine; tyrosine kinase; kinase inhibitor ... See more keywords
Focal Segmental Sclerosis Associated with the Novel Multi-tyrosine Kinase Inhibitor Ponatinib: A Case Report.
Sign Up to like & getrecommendations! Published in 2023 at "Internal medicine"
DOI: 10.2169/internalmedicine.1283-22
Abstract: Ponatinib is a novel multi-tyrosine kinase inhibitor (TKI) with potent inhibitory activity against refractory chronic myeloid leukemia (CML). Despite its high clinical efficacy, ponatinib induces various adverse events due to its multi-target characteristic. However, renal… read more here.
Keywords: focal segmental; novel multi; kinase inhibitor; tyrosine kinase ... See more keywords